(Q53340162)
Statements
Exploring drug delivery for the DOT1L inhibitor pinometostat (EPZ-5676): Subcutaneous administration as an alternative to continuous IV infusion, in the pursuit of an epigenetic target. (English)
Nigel J Waters
Scott R Daigle
Bruce N Rehlaender
Aravind Basavapathruni
Carly T Campbell
Tyler B Jensen
Brett F Truitt
Edward J Olhava
Roy M Pollock
Kim A Stickland
Angelos Dovletoglou
15 September 2015
220
Pt B
758-765